U.S. Markets closed

Enzon Pharmaceuticals, Inc. (ENZN)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.24+0.01 (+2.56%)
At close: 3:57PM EDT
People also watch
QLTIALKSPDLIMYGNARQL

Enzon Pharmaceuticals, Inc.

20 Commerce Drive
Suite 135
Cranford, NJ 07016
United States
732-980-4500
http://enzon.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Mr. Andrew Rackear J.D.Chief Exec. Officer and Sec.139.16kN/A63
Mr. Richard L. Feinstein CPAChief Financial Officer and VP of Fin.159.51kN/A74
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The company’s marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn’s disease. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Cranford, New Jersey.

Corporate Governance

Enzon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.